GlassScriptPhysician profile
Noel Laudi
NPI 1235221110
$273,634.41
in general payments reported to CMS, 2019-2025
19 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $35K · 2021: $89K · 2022: $45K · 2023: $42K · 2024: $1,375 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $11K · Consulting Fee: $1,505 · Food and Beverage: $1,088 · Honoraria: $200 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,015.00 |
| Travel and Lodging | $10,546.20 |
| Consulting Fee | $1,505.00 |
| Food and Beverage | $1,088.35 |
| Honoraria | $200.00 |
| Education | $156.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $56,560.09 | 2020-2023 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $53,843.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $43,612.23 | 2019-2023 | Lynparza, Keytruda |
| Beigene USA, INC. | $31,706.49 | 2020-2023 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $22,047.55 | 2020-2024 | Calquence |
| Janssen Biotech, INC. | $20,791.36 | 2019-2024 | Rybrevant |
| Daiichi Sankyo INC. | $19,722.51 | 2020-2023 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $9,911.47 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $4,799.96 | 2019 | |
| Karyopharm Therapeutics INC. | $2,625.00 | 2020 | |
| Genzyme Corporation | $2,221.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $2,061.23 | 2019 | |
| Jazz Pharmaceuticals INC. | $1,500.00 | 2021 | |
| Seagen INC. | $1,494.00 | 2021 | |
| Beigene, LTD. | $450.00 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.00 | 2025 | |
| Allergan, INC. | $120.00 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Laudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.